Lil­ly's Retev­mo lands new ac­cel­er­at­ed ap­proval for pe­di­atric can­cers

The FDA on Wednes­day grant­ed an­oth­er ac­cel­er­at­ed ap­proval to Eli Lil­ly’s can­cer drug Retev­mo, this time for pe­di­atric pa­tients age 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.